Melane Sampson, Author at BioTuesdays

Developments

Onco-Innovations’ technology aims to transform cancer treatments

Onco-Innovations (CSE:ONCO; FRANKFURT:W1H; WKN:A3EKSZ) has announced that its exclusively-licensed, patented polynucleotide kinase 3’-phosphates (PNKP) inhibitors technology holds the potential to significantly enhance...

January 9, 2025

Executive Moves

Dr. Elena Ratner joins Eterna’s BOD

Eterna Therapeutics (NASDAQ:ERNA) has announced the appointment of Elena Ratner, MD, MBA, to its board of directors. The company states that Dr. Ratner will spearhead the strategic direction of Eterna’s efforts to...

January 9, 2025

Developments

MOBILion spotlights 100th peer-reviewed publication featuring its separations technology platform

Closely held MOBILion Systems has announced that, as of December 24, 2024, its foundational Structures for Lossless Ion Manipulation (SLIM) platform technology has been highlighted in 100 peer-reviewed publications in...

January 8, 2025

Executive Moves

Tonix appoints Gary Ainsworth as VP of market access

Tonix Pharmaceuticals (NASDAQ:TNXP) has announced the appointment of Gary Ainsworth as vice president of market access, effective immediately. Mr. Ainsworth brings extensive pharmaceutical and healthcare consultancy...

January 8, 2025

Developments

MediPharm expands Brazilian presence through agreement with Teuto

MediPharm Labs (TSX:LABS; OTCQX:MEDIF) has announced an agreement with Laboratório Teuto to expand its reach into the Brazilian medical cannabis market. The company states that it has been working closely with Teuto on...

January 8, 2025

Developments

FDA clears Solid’s IND application for SGT-212 in FA

Solid Biosciences (NASDAQ:SLBD) announced that the FDA has cleared its IND application for SGT-212, a first-in-industry dual-route of administration gene therapy designed to treat the neurologic and cardiac...

January 8, 2025

Developments

CytoMed and SunAct sign agreement for solid tumor treatment trial in India

CytoMed Therapeutics (NASDAQ:GDTC) has announced the signing of a five-year business and research collaboration agreement with the SunAct Cancer Institute to investigate the efficacy, safety, tolerability, and potency...

January 7, 2025

Developments

OraSure’s HIV Self-Test approved for adolescents

OraSure Technologies (NASDAQ:OSUR) has announced that the approved age range for its OraQuick HIV Self-Test has been expanded to include individuals aged 14 and older. The company cites data from the Centers for Disease...

January 7, 2025

Feature

IMUNON harmonizing life’s blueprint with immune system through DNA-based therapies

IMUNON (NASDAQ:IMNN) is advancing a distinctive approach to treating of some of the world’s most challenging diseases, leveraging a portfolio of proprietary immunology and DNA-based platforms that harness the body’s...

January 7, 2025

Developments

Portage relaunches independent subsidiary with Peter Molloy as CEO

Portage Biotech (NASDAQ:PRTG) has announced the relaunch of its wholly-owned adenosine subsidiary, Cyncado Therapeutics, as an independently managed company headed by Peter Molloy as CEO. The company reports that...

January 6, 2025

Author - Melane Sampson

Onco-Innovations’ technology aims to transform cancer treatments

Dr. Elena Ratner joins Eterna’s BOD

MOBILion spotlights 100th peer-reviewed publication featuring its separations technology platform

Tonix appoints Gary Ainsworth as VP of market access

MediPharm expands Brazilian presence through agreement with Teuto

FDA clears Solid’s IND application for SGT-212 in FA

CytoMed and SunAct sign agreement for solid tumor treatment trial in India

OraSure’s HIV Self-Test approved for adolescents

IMUNON harmonizing life’s blueprint with immune system through DNA-based therapies

Portage relaunches independent subsidiary with Peter Molloy as CEO

Subscribe